Ventricular fractional shortening in 108 dogs with malignant lymphoma undergoing chemotherapy with a cyclic combination protocol including doxorubicin

G. Tater; N. Eberle; S. Hungerbuehler; A. Joetzke; I. Nolte; G. Wess; D. Betz

doi:10.1055/s-0038-1623648

Tierärztliche Praxis Ausgabe K: Kleintiere / Heimtiere, Table of Contents

Tierarztl Prax Ausg K Kleintiere Heimtiere 2012; 40(04): 261-266
DOI: 10.1055/s-0038-1623648

Original Article

Schattauer GmbH

Ventricular fractional shortening in 108 dogs with malignant lymphoma undergoing chemotherapy with a cyclic combination protocol including doxorubicin

Linksventrikuläre Verkürzungsfraktion bei 108 Hunden mit malignem Lymphom unter zyklischer Kombinationschemotherapie mit Doxorubicin

Authors

G. Tater

¹Small Animal Hospital, University of Veterinary Medicine, Hannover, Germany
N. Eberle

¹Small Animal Hospital, University of Veterinary Medicine, Hannover, Germany
S. Hungerbuehler

¹Small Animal Hospital, University of Veterinary Medicine, Hannover, Germany
A. Joetzke

¹Small Animal Hospital, University of Veterinary Medicine, Hannover, Germany
I. Nolte

¹Small Animal Hospital, University of Veterinary Medicine, Hannover, Germany
G. Wess

²Clinic of Small Animal Internal Medicine, Ludwig-Maximilian-University, Munich, Germany
D. Betz

¹Small Animal Hospital, University of Veterinary Medicine, Hannover, Germany

Abstract

Summary

Objective: The aim of this study was to evaluate whether changes in the left ventricular fractional shortening (LVFS) can be detected in dogs with malignant lymphoma undergoing a cyclic combination chemotherapy protocol including doxorubicin.

Hypothesis: Left ventricular fractional shortening as a stand-alone measurement will not show a significant change during the cyclic combination protocol.

Material and methods: In this retrospective study, the records of dogs with malignant lymphoma treated between April 2001 and October 2010 were reviewed. Inclusion criteria comprised: a diagnosis of malignant lymphoma, a cyclic combination chemotherapy (including L-asparaginase, vincristine, cyclophosphamide, doxorubicin and prednisolone), and an echocardiographic examination by an experienced examiner before treatment and after each doxorubicin administration.

Results: One hundred and eight dogs were included and a total of 446 LVFS measurements had been performed. Patients were divided into four groups according to the number of doxorubicin administrations. Median LVFS did not change significantly during the cyclic combination protocol in all groups. All median LVFS values remained above the lower reference value of 25%.

Conclusion and clinical relevance: The measurement of LVFS did not show a significant change during the cyclic combination protocol treatment including doxorubicin in this population of dogs. Therefore either this cyclic combination protocol does not cause a systolic dysfunction or LVFS is not sensitive enough to detect early changes. Newer methods that are more sensitive then LVFS might be necessary to detect such changes.

Zusammenfassung

Gegenstand und Ziel: dieser Studie war die echokardiographische Evaluierung potenzieller Veränderungen der linksventrikulären Verkürzungsfraktion (Left Ventricular Fractional Shortening, LVFS) bei Hunden mit malignem Lymphom unter zyklischer Kombinationschemotherapie mit Doxorubicin.

Hypothese: Die LVFS als alleiniger Parameter kann keine signifikanten Änderungen im Protokollverlauf darstellen

Material und Methoden: Diese retrospektive Studie umfasst die Daten der Hunde, die zwischen April 2001 und Oktober 2010 wegen eines malignen Lymphoms behandelt wurden. Einschlusskriterien waren zum einen die Diagnose eines malignen Lymphoms, eine zyklische Kombinationschemotherapie (L-Asparaginase, Vincristin, Cyclophosphamid, Doxorubicin und Prednisolon), und zum anderen eine echokardiographische Evaluierung vor und nach jeder Doxorubicinapplikation.

Ergebnisse: 108 Hunde gingen in die Studie ein. Insgesamt waren 446 LVFSMessungen durchgeführt worden. Entsprechend der Anzahl der Doxorubicingaben erfolgte eine Einteilung der Hunde in vier Gruppen. Die mediane LVFS zeigte während des zyklischen Behandlungsprotokolls in allen Gruppen keine signifikanten Unterschiede. Alle erhobenen medianen Werte lagen über dem unteren beschriebenen Referenzbereich von 25%.

Schlussfolgerung und klinische Relevanz: Die Messung der Verkürzungsfraktion ließ während der gesamten Behandlungsdauer keinen signifikanten Unterschied erkennen. Dies kann durch die mangelnde Sensitivität der Methode bedingt sein oder dadurch, dass die zyklische Kombinationschemotherapie keine systolische Dysfunktion verursacht. Neuere Messmodalitäten mit höherer Sensitivität könnten hier genaueren Aufschluss bieten.

Key words

Fractional shortening - doxorubicin - malignant lymphoma - dog

Schlüsselwörter

Linksventrikuläre Verkürzungsfraktion - Doxorubicin - malignes Lymphom - Hund

Full Text

References

References
1 Baumwart RD, Orvalho J. et al. Evaluation of serum cardiac troponin I concentration in Boxers with arrhythmogenic right ventricular cardiomyopathy. Am J Vet Res 2007; 68 (05) 524-528.
2 Belham M, Kruger A. et al. Monitoring left ventricular function in adults receiving anthracycline-containing chemotherapy. Eur J Heart Fail 2007; 09 (04) 409-414.
3 Boon JA. Appendix IV. In: Manuel of Veterinary Echocardiography. Boon JA. ed. Boltimor Mariland: Lippincott Williams & Wilkins; 1998: 453-463.
4 Chetboul V, Tidholm A, Nicolle A, Sampedrano CC, Gouni V, Pouchelon JL, Lefebvre HP, Concordet D. Effects of animal position and number of repeated measurements on selected two-dimensional and M-mode echocardiographic variables in healthy dogs. J Am Vet Med Assoc 2005; 227 (05) 743-747.
5 Chetboul V, Serres F, Gouni V, Tissier R, Pouchelon JL. Radial strain and strain rate by two-dimensional speckle tracking echocardiography and the tissue velocity based technique in the dog. J Vet Cardiol 2007; 09 (02) 69-81.
6 Chlebowski RT. Adriamycin (doxorubicin) cardiotoxicity: a review. West J Med 1979; 131 (05) 364-368.
7 Cornell CC, Kittleson MD. et al. Allometric scaling of M-mode cardiac measurements in normal adult dogs. J Vet Intern Med 2004; 18 (03) 311-321.
8 Culmsee K, Simon D. et al. Possibilities of flow cytometric analysis for immunophenotypic characterization of canine lymphoma. J Vet Med A Physiol Pathol Clin Med 2001; 48 (04) 199-206.
9 Ditchy RV, LeWinter MM, Higgins CB. Acute effects of doxorubicin (adriamycin) on left ventricular function in dogs. Int J Cardiol 1984; 06 (03) 341-353.
10 Dobson JM, Samuel S. et al. Canine neoplasia in the UK: estimates of incidence rates from a population of insured dogs. J Small Anim Pract 2002; 43 (06) 240-246.
11 Dorn CR, Taylor DO. et al. Survey of animal neoplasms in Alameda and Contra Costa Counties, California. II. Cancer morbidity in dogs and cats from Alameda County. J Natl Cancer Inst 1968; 40 (02) 307-318.
12 Hammer AS, Couto CG. et al. Efficacy and toxicity of VAC chemotherapy (vincristine, doxorubicin, and cyclophosphamide) in dogs with hemangiosarcoma. J Vet Intern Med 1991; 05 (03) 160-166.
13 Killich M, Hartmann K, Wess G. Messung der myokardialen Geschwindgkeit mittels Gewebe-Doppler beim gesunden Hund. Tierärztl Prax 2011; 39 (K): 69-78.
14 Kittelson MD, Kienle RD. Echocardiography. In: Small Animal Cardiovascular Medicine. Kittelson MD, Kienle RD. eds. St. Louis: Mosby; 1998: 95-117.
15 Kittelson MD, Kienle RD. Primary myocardial disease leading to chronic myocardial failure – Doxorubicin induced myocardial failure. In: Small Animal Cardiovascular Medicine. Kittelson MD, Kienle RD. eds. St. Louis: Mosby; 1998: 340.
16 Mauldin GE, Fox PR. et al. Doxorubicin-induced cardiotoxicosis. Clinical features in 32 dogs. J Vet Intern Med 1992; 06 (02) 82-88.
17 Moise NS, Fox PR. Echocardiography and Doppler imaging. In: Textbook of Canine and Feline Cardiology. 2nd. edn. Fox P R, Sisson D, Moise NS. eds. Philadelphia: Saunders; 1999: 130-171.
18 Ogilvie GK, Richardson RC. et al. Acute and short-term toxicoses associated with the administration of doxorubicin to dogs with malignant tumors. J Am Vet Med Assoc 1989; 195 (11) 1584-1587.
19 Ogilvie GK, Powers BE. et al. Surgery and doxorubicin in dogs with hemangiosarcoma. J Vet Intern Med 1996; 10 (06) 379-384.
20 O’Keefe DA, Sisson DD. et al. Systemic toxicity associated with doxorubicin administration in cats. J Vet Intern Med 1993; 07 (05) 309-317.
21 Owen L. TNM classification of tumors in domestic animals. In: World Health Organization. Geneva: 1980: 46-47.
22 Oyama MA, Sisson DD. Cardiac troponin-I concentration in dogs with cardiac disease. J Vet Intern Med 2004; 18 (06) 831-839.
23 Page RL, Keene BW. Doxorubicin cardiomyopathy. In: Kirk’s Current Veterinary Therapy; Vol. XI. Kirk RW, Bonagura JD. eds. St. Louis: Saunders; 1992: 783.
24 Saltiel E, McGuire W. Doxorubicin (adriamycin) cardiomyopathy. West J Med 1983; 139 (03) 332-341.
25 Selting KA, Lana SE. et al. Cardiac troponin I in canine patients with lymphoma and osteosarcoma receiving doxorubicin: comparison with clinical heart disease in a retrospective analysis. Vet Comp Oncol 2004; 02 (03) 142-156.
26 Shah HR, Vaynblat M, Ramder G, Cunningham Jr JN, Chiavarelli M. Experimental Cardiomyopathy as a model of chronic heart failure. J Invest Surg 1997; 10 (06) 387-396.
27 Simak J, Keller L, Killich M, Hartmann K, Wess G. Color-coded longitudinal interventricular septal tissue velocity imaging, strain and strain rate in healthy Doberman Pinschers. J Vet Cardiol 2011; 13 (01) 1-11.
28 Simon D, Nolte I. et al. Treatment of dogs with lymphoma using a 12-week, maintenance-free combination chemotherapy protocol. J Vet Intern Med 2006; 20 (04) 948-954.
29 Sisson D, O’Grady MR, Calvert CA. Myocardial diseases of dogs. In: Textbook of Canine and Feline Cardiology. 2nd. edn. Fox PR, Sisson D, Moise NS. eds. Philadelphia: Saunders; 581-619.
30 Sorenmo K, Duda L. et al. Canine hemangiosarcoma treated with standard chemotherapy and minocycline. J Vet Intern Med 2000; 14 (04) 395-398.
31 Sorenmo KU, Jeglum KA. et al. Chemotherapy of canine hemangiosarcoma with doxorubicin and cyclophosphamide. J Vet Intern Med 1993; 07 (06) 370-376.
32 Sorenmo K, Samluk M. et al. Clinical and pharmacokinetic characteristics of intracavitary administration of pegylated liposomal encapsulated doxorubicin in dogs with splenic hemangiosarcoma. J Vet Intern Med 2007; 21 (06) 1347-1354.
33 Sorenmo KU, Baez JL. et al. Efficacy and toxicity of a dose-intensified doxorubicin protocol in canine hemangiosarcoma. J Vet Intern Med 2004; 18 (02) 209-213.
34 Thomas WP, Gaber CE. et al. Recommendations for standards in transthoracic two-dimensional echocardiography in the dog and cat. Echocardiography Committee of the Specialty of Cardiology, American College of Veterinary Internal Medicine. J Vet Intern Med 1993; 07 (04) 247-252.
35 Toyoda Y, Okada M, Kasherm MA. A canine model of dilated cardiomyopathy induced by repetitive intracoronary doxorubicin administration. J Thorac Cardiovasc Surg 1998; 115 (06) 1367-1373.
36 Trafny DJ, Oyama MA. et al. Cardiac troponin-I concentrations in dogs with bradyarrhythmias before and after artificial pacing. J Vet Cardiol 2010; 12 (03) 183-190.
37 Van Vleet JF, Ferrans VJ. et al. Cardiac disease induced by chronic adriamycin administration in dogs and an evaluation of vitamin E and selenium as cardioprotectants. Am J Pathol 1980; 99 (01) 13-42.
38 Wells SM, Sleeper M. Cardiac troponins. J Vet Emerg Crit Care 2008; 08 (03) 235-245.
39 Wess G, Simak J. et al. Cardiac troponin I in Doberman Pinschers with cardiomyopathy. J Vet Intern Med 2010; 24 (04) 843-849.
40 Wess G, Mäurer J, Julia J, Hartmann K. Use of Simpson’s method of disc to detect early echocardiographic changes in Doberman Pinschers with dilated cardiomyopathy. J Vet Intern Med 2010; 24 (05) 1069-1076.